Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 13/20 | 0.46 |
| ▸ | KDM5A | P29375 | 2/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.41 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580744 | 0.89 | KDM4C (0.48) | KDM5AKDM5BKDM4EKDM6BKDM5C | |
| SCHEMBL581445 | 0.85 | MRGPRX4 (0.46) | KDM5AKDM5BKDM4EKDM6BKDM5C | |
| SCHEMBL581494 | 0.85 | MRGPRX4 (0.51) | GPR52KDM4CMRGPRX4CYP3A4 | |
| SCHEMBL581308 | 0.82 | KDM4E (0.46) | KDM5AKDM5BKDM4EKDM6BKDM5C | |
| SCHEMBL581173 | 0.81 | KDM5B (0.56) | KDM5AKDM5BKDM4EKDM6BKDM5C | |
| SCHEMBL580683 | 0.81 | MRGPRX4 (0.55) | KDM5AKDM5BKDM4EKDM6BKDM5C | |
| SCHEMBL23824210 | 0.80 | GPR52 (0.52) | GPR52KDM4ECYP3A4HTT | |
| SCHEMBL581939 | 0.79 | MRGPRX4 (0.51) | GPR52MRGPRX4CYP3A4 | |
| Hydrochloric Acid SCHEMBL582456 | 0.79 | KDM5B (0.46) | GPR52KDM5AKDM5BKDM4EKDM6B | |
| SCHEMBL580763 | 0.79 | NOTUM (0.46) | KDM5AKDM5BKDM4EKDM6BKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | GPR52 153/4885KDM5A 3697/4885KDM5B 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.